Study identifier:D9612L00113
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A cross-sectional, Canadian, multi-centre study of symptom burden and clinical management in subjects with Gastroesophageal Reflux Disease (GERD) RANGE: Retrospective ANalysis of GErd
GERD
N/A
No
-
All
379
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
This is a cross-sectional study of symptom burden and clinical management. A subset of patients who have attended the Primary Care (PC) office with reflux symptoms during a retrospective period of 4 months (Index Visit) are invited to complete health survey questionnaires and partake in a subject-physician/study nurse interview (Visit 1), in order to assess the type, intensity and frequency of GERD symptoms at both visits and describe the treatment provided. Additionally, the impact of GERD on subjects’ life, productivity and willingness to pay for GERD symptom relief will be explored. This design will give a “real-life” clinical practice picture in a representative population of PC doctors and subjects.
Location
Location
CORNWALL, ON, Canada
Location
EDMONTON, AB, Canada
Location
EXETER, ON, Canada
Location
HAMILTON, ON, Canada
Location
KANATA, ON, Canada
Location
LONDON, ON, Canada
Location
NEPEAN, ON, Canada
Location
NEWMARKET, ON, Canada
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.